Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

Completed

• Conditions: Transplantation
• Interventions: Drug: Sirolimus

• Registration Number: NCT00195195
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-19
• Primary Completion: 2008-06
• Study Completion: 2008-06
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-26
• Last Update Posted: 2012-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Transplantation patients treated with sirolimus (Rapamune).

Exclusion Criteria

• Patients must be able to give informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Sirolimus	Sirolimus